![]() |
Actavis makes move for Pliva |
Novartis to challenge AstraZeneca |
Six in hospital after clinical trial disaster |
![]() |
Pharma news in brief |
NHS news in brief |
R&D news in brief |
Phase III Sativex trial results Shares in GW Pharmaceuticals have dropped sharply by 25 per cent after the firm released preliminary results from a phase III trial of its experimental cannabis-based multiple sclerosis drug, Sativex. The study, which measured the drug's effect on spasticity in MS sufferers, showed that patients who complied with the study protocol showed a statistically significant improvement in the primary outcome measure. However, improvement in the intention to treat population (i.e. all patients regardless of whether they complied with the protocol) was not of statistical significance. We will proceed so that the next regulatory filing in Europe has the maximum chance of success across the indications and across the major markets, said Geoffrey Guy, executive chairman at GW. Slow-release vaccine on course Protelos shines in study |
OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...